Promising antitumour activity has been noted with HDAC inhibitors in several human tumours, such as hepatocellular carcinoma, breast cancer and head and neck squamous cell carcinoma.51, 52. This evidence concerns the gene HDAC9 and head and neck squamous cell carcinoma.